Triglav Skladi’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$63.6M Buy
53,033
+3,821
+8% +$3.9M 3.35% 8
2026
Q1
$45.3M Buy
49,212
+1,566
+3% +$1.59M 3.17% 8
2025
Q4
$51.2M Sell
47,646
-3,922
-8% -$3.75M 3.23% 9
2025
Q3
$39.3M Sell
51,568
-2,468
-5% -$1.84M 2.57% 9
2025
Q2
$42.1M Buy
54,036
+791
+1% +$615K 3.04% 9
2025
Q1
$44M Sell
53,245
-2,303
-4% -$1.92M 3.68% 7
2024
Q4
$42.9M Buy
+55,548
New +$46M 3.37% 7

Other funds holding LLY

Triglav Skladi's LLY Position: Q2 2026 in Review

Triglav Skladi increased its Eli Lilly (LLY) stake by 7.8% in Q2 2026, buying an estimated $3.9M and bringing the position to 53,033 shares worth $63.6M. The position accounts for 3.35% of the portfolio, ranked #8.

Triglav Skladi first reported a position in LLY in Q4 2024 and has held it in 7 quarters since. 4,624 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Triglav Skladi held 53,033 shares of Eli Lilly worth $63.6M as of Q2 2026.
  • Triglav Skladi bought 3,821 Eli Lilly shares in Q2 2026, an estimated $3.9M.
  • Eli Lilly made up 3.35% of Triglav Skladi's portfolio in Q2 2026, its #8 holding.
  • Triglav Skladi first reported a position in Eli Lilly in Q4 2024 and has held it in 7 quarters since.
  • 4,624 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Triglav Skladi's 13F filing for Q2 2026, filed 11 Aug 2026.